10-QPeriod: Q1 FY2007

QUEST DIAGNOSTICS INC Quarterly Report for Q1 Ended Mar 31, 2007

Filed April 30, 2007For Securities:DGX

Summary

Quest Diagnostics reported mixed financial results for the first quarter ended March 31, 2007. While net revenues saw a slight decrease of 1.7% year-over-year to $1.53 billion, primarily due to the loss of a major contract with UnitedHealthcare (UNH), the company also faced challenges from severe weather. However, strategic acquisitions, including HemoCue, Focus Diagnostics, and Enterix, contributed positively to revenue growth in other segments. The company's operating income declined significantly, impacted by lower volumes and increased operating costs as a percentage of revenue. These increases were driven by the UNH contract change, workforce reduction charges, and integration costs from acquisitions. Despite these headwinds, Quest Diagnostics remains focused on cost management and strategic growth, with a significant $2 billion acquisition of AmeriPath announced shortly after the quarter's end, demonstrating a commitment to expanding its market position in specialized testing.

Key Highlights

  • 1Net revenues decreased by 1.7% to $1.53 billion for the first quarter of 2007, compared to the prior year, primarily impacted by the loss of the UnitedHealthcare (UNH) contract.
  • 2Operating income decreased substantially to $200.9 million from $258.7 million in the prior year, reflecting lower volumes and increased operating expenses as a percentage of revenue.
  • 3The company acquired HemoCue for approximately $450 million, strengthening its position in point-of-care testing and expanding its global presence.
  • 4Acquisitions of Focus Diagnostics and Enterix in 2006 also contributed to revenue growth in the 'all other operating segments'.
  • 5Discontinued operations, primarily related to NID, continued to result in a net loss of $1.6 million for the quarter.
  • 6Quest Diagnostics announced a significant agreement to acquire AmeriPath for approximately $2 billion shortly after the quarter end, signaling a strategic move into specialized pathology services.
  • 7The company repurchased approximately 2.1 million shares of common stock for $105 million during the quarter.

Frequently Asked Questions

The primary reason for the decline in net revenues was the change in contract status with UnitedHealthcare (UNH), a major client. Quest Diagnostics was no longer a national contracted provider for UNH starting January 1, 2007, which significantly impacted revenues. Severe storms in the central United States also contributed to a lesser extent.

The acquisition of HemoCue, completed in January 2007, contributed to revenue growth in the 'all other operating segments' category. While the acquisition itself involved significant cash outlay ($450 million), its direct impact on the first quarter's net income was positive through added revenue, though it also incurred some integration and R&D expensing costs.

Quest Diagnostics estimated that not being a contracted provider for UNH would reduce revenue growth by 7% to 10% in 2007. While the company expected to lose the majority of UNH business by the end of 2007, they are actively managing costs and focusing on retaining physician and patient choice, and educating the market about provider differences. The company is also pursuing appropriate reimbursement for services provided to UNH members as a non-contracted provider.

The announced acquisition of AmeriPath, Inc. for approximately $2 billion is a major strategic move. It is expected to significantly expand Quest Diagnostics' presence in specialized testing, particularly dermatopathology and anatomic pathology. While the deal is expected to have a minimal impact on 2007 earnings per share, it is anticipated to be modestly accretive in 2008, demonstrating a strong commitment to future growth and market leadership in higher-margin service areas.